Robert Califf

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes
    Robert M Califf
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 149:S91-9. 2005
  2. ncbi request reprint Integrating quality into the cycle of therapeutic development
    Robert M Califf
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 40:1895-901. 2002
  3. ncbi request reprint Clinical quality in non-ST-elevation acute coronary syndromes
    Robert M Califf
    The Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27710, USA
    Am J Med 120:930-5. 2007
  4. ncbi request reprint Need for centers to care for patients with acute coronary syndromes
    Robert M Califf
    Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 107:1467-70. 2003
  5. ncbi request reprint Toward protecting the safety of participants in clinical trials
    Robert M Califf
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Control Clin Trials 24:256-71. 2003
  6. ncbi request reprint Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics
    Robert M Califf
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Health Aff (Millwood) 26:62-74. 2007
  7. ncbi request reprint Health Insurance Portability and Accountability Act (HIPAA): must there be a trade-off between privacy and quality of health care, or can we advance both?
    Robert M Califf
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27705, USA
    Circulation 108:915-8. 2003
  8. ncbi request reprint Issues facing clinical trials of the future
    R M Califf
    Duke Clinical Research Institute and Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Intern Med 254:426-33. 2003
  9. ncbi request reprint Supplement on acute coronary syndromes: introduction
    Robert M Califf
    Duke Clinical Research Institute, P O Box 17969, Durham, NC 27710, USA
    Circulation 108:III1-5. 2003
  10. ncbi request reprint Clinical trials bureaucracy: unintended consequences of well-intentioned policy
    Robert M Califf
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Clin Trials 3:496-502. 2006

Research Grants

  1. ESCAPE Mechanistic Substudies
    Robert Califf; Fiscal Year: 2003

Detail Information

Publications113 found, 100 shown here

  1. ncbi request reprint A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes
    Robert M Califf
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 149:S91-9. 2005
    ..Contemporary guidelines from the American College of Cardiology/American Heart Association call for use of low-molecular-weight heparin or unfractionated heparin (UFH)...
  2. ncbi request reprint Integrating quality into the cycle of therapeutic development
    Robert M Califf
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 40:1895-901. 2002
    ..Such a model would serve as a basic approach to cardiovascular medicine that is necessary, but not sufficient, to those wishing to provide the best care for their patients...
  3. ncbi request reprint Clinical quality in non-ST-elevation acute coronary syndromes
    Robert M Califf
    The Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27710, USA
    Am J Med 120:930-5. 2007
    ....
  4. ncbi request reprint Need for centers to care for patients with acute coronary syndromes
    Robert M Califf
    Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 107:1467-70. 2003
  5. ncbi request reprint Toward protecting the safety of participants in clinical trials
    Robert M Califf
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Control Clin Trials 24:256-71. 2003
    ..DMC composition and functions should be standardized and regulations should be harmonized nationally and internationally. Finally, there should be a concerted effort to study the efficacy of various components of the system...
  6. ncbi request reprint Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics
    Robert M Califf
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Health Aff (Millwood) 26:62-74. 2007
    ....
  7. ncbi request reprint Health Insurance Portability and Accountability Act (HIPAA): must there be a trade-off between privacy and quality of health care, or can we advance both?
    Robert M Califf
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27705, USA
    Circulation 108:915-8. 2003
  8. ncbi request reprint Issues facing clinical trials of the future
    R M Califf
    Duke Clinical Research Institute and Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Intern Med 254:426-33. 2003
    ..A proposed organization for future trials also is elucidated...
  9. ncbi request reprint Supplement on acute coronary syndromes: introduction
    Robert M Califf
    Duke Clinical Research Institute, P O Box 17969, Durham, NC 27710, USA
    Circulation 108:III1-5. 2003
  10. ncbi request reprint Clinical trials bureaucracy: unintended consequences of well-intentioned policy
    Robert M Califf
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Clin Trials 3:496-502. 2006
    ..However, this structure has not been adequately assessed to ensure that regulations governing human subjects research actually produce the desired effects...
  11. ncbi request reprint Novel approaches to clinical trials: device-related infections
    Robert M Califf
    Division of Cardiology, Duke University Medical Center and the Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 147:599-604. 2004
    ..The purpose of this manuscript is to discuss issues about the design of studies and their organization...
  12. ncbi request reprint Benefit the patient, manage the risk: a system goal
    Robert M Califf
    Division of Cardiology, Department of Medicine, The Duke Clinical Research Institute, and the Centers for Education and Research on Therapeutics, Duke University Medical Center, Durham, NC, USA
    Pharmacoepidemiol Drug Saf 13:269-76. 2004
  13. pmc Translating clinical trials into practice
    Robert M Califf
    Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Tex Heart Inst J 33:192-6. 2006
  14. ncbi request reprint Evaluation of diagnostic imaging technologies and therapeutics devices: better information for better decisions: proceedings of a multidisciplinary workshop
    Robert M Califf
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 152:50-8. 2006
    ....
  15. ncbi request reprint A time of accelerated change in academic cardiovascular medicine: implications for academic divisions of cardiology and their training programs
    Robert M Califf
    Duke Clinical Research Institute, the Duke Heart Center, Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27701, USA
    J Am Coll Cardiol 44:1957-65. 2004
    ..Academic programs should benchmark their activities to ensure responsible resource allocation so that cardiologists of the future will be trained in an environment stimulating excellence and creativity...
  16. ncbi request reprint Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics
    Robert M Califf
    Centers for Education and Research on Therapeutics Coordinating Center, Duke University Medical Center, Durham, NC, USA
    Pharmacoepidemiol Drug Saf 16:5-16. 2007
    ..Key categories for the establishment of a research agenda to fill in gaps in our understanding of assessing benefit were developed by the group...
  17. ncbi request reprint Matching resources to treatment decisions for patients with acute coronary syndromes
    Robert M Califf
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705 3076, USA
    Clin Cardiol 25:I2-8. 2002
    ..Because the amount of evidence in acute coronary syndromes (ACS) exceeds other areas of medicine, therapies for ACS will undergo increasingly intense scrutiny...
  18. ncbi request reprint Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial
    R M Califf
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 101:2231-8. 2000
    ..When a patient survives thrombolysis for acute myocardial infarction, little information from large studies exists from which to estimate prognosis during follow-up visits...
  19. ncbi request reprint Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?
    Robert M Califf
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Stat Med 21:2889-97. 2002
    ..The case of the platelet glycoprotein IIb/IIIa inhibitor, abciximab, is used to illustrate many of the issues surrounding the collection, interpretation, and (mis) application of cost-effectiveness data...
  20. doi request reprint Cardiovascular research in the elderly: challenges, opportunities, and impact
    Robert M Califf
    Duke Clinical Research Institute, Box 17969, Durham, NC 27715, USA
    Postgrad Med 112:6-11. 2002
    ..Therefore, although treatments must continue to be applied to individuals based on their preferences, the evidence for these treatments must not summarily discriminate on the basis of age...
  21. ncbi request reprint Introduction
    Robert M Califf
    Durham, NC 27715, USA
    Postgrad Med 112:5. 2002
    ..The inconsistent and conservative use of medical interventions may contribute to the adverse outcomes so often seen in the elderly with cardiovascular disease...
  22. ncbi request reprint Myonecrosis after revascularization procedures
    R M Califf
    Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 31:241-51. 1998
    ..In addition, tracking of enzyme levels in clinical trials is needed to determine whether interventions that reduce periprocedural enzyme elevation also improve mortality...
  23. ncbi request reprint Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators
    R M Califf
    Department of Medicine Cardiology, Duke University Medical Center, Durham, N C 27710, USA
    Am Heart J 133:630-9. 1997
    ..Patients with acute myocardial infarction who had more high-risk characteristics derived a greater absolute benefit from treatment with accelerated TPA versus streptokinase...
  24. doi request reprint Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial)
    Robert M Califf
    Duke Translational Medicine Institute, Durham, North Carolina, USA
    Am J Cardiol 104:151-7. 2009
    ..In conclusion, no evidence was found of adverse interactions between the angiotensin-receptor blocker valsartan and beta blockers or of a negative effect of the combination of valsartan, captopril, and beta blockers...
  25. ncbi request reprint Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
    ....
  26. ncbi request reprint Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials)
    Abdallah G Rebeiz
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 95:611-4. 2005
    ..7% vs 48.0% with >/=50% ST-segment resolution, p = 0.03) and sustained over 180 minutes after drug administration; this transient benefit may suggest a time frame when more optimal percutaneous coronary intervention can be performed...
  27. ncbi request reprint Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 150:323-9. 2005
    ..We conducted a prospective economic evaluation to compare within-trial resource use, costs, and quality of life in patients receiving valsartan, captopril, or both after MI...
  28. ncbi request reprint An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase
    David M Kent
    Division of Clinical Care Research, Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Med 113:104-11. 2002
    ..3% 30-day mortality, compared with a mortality of 7.3% among those treated with streptokinase, despite a greater risk of intracranial hemorrhage with tPA. However, in part because of its higher cost, tPA has not been adopted universally...
  29. ncbi request reprint Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Durham, NC, USA
    Am Heart J 148:122-8. 2004
    ..We sought to compare resource use, costs, and health outcomes among patients taking prescribed therapy for heart failure and randomly assigned to receive valsartan or placebo...
  30. ncbi request reprint Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial
    Melvin R Echols
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Card Fail 12:684-8. 2006
    ..Recent data suggest that differences in response to therapy and survival exist between African Americans and Caucasians with heart failure. Whether these differences exist in acute decompensated heart failure (ADHF) is uncertain...
  31. ncbi request reprint The case for practical clinical trials in psychiatry
    John S March
    Department of Psychiatry and Behavioral Sciences, Duke Child and Family Study Center, 718 Rutherford St, Durham, NC 27705, USA
    Am J Psychiatry 162:836-46. 2005
    ..The authors present the case for psychiatry's adoption of the practical clinical trials model, which is widely used in research in other areas of medicine...
  32. ncbi request reprint Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome
    Hassan Kassem-Moussa
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 148:439-46. 2004
    ..Stroke is a rare but serious event that complicates the course of patients with acute coronary syndromes (ACS). The type, outcome, and risk factors of stroke occurring in stabilized patients with ACS have not been previously reported...
  33. ncbi request reprint Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)
    Thaddeus R Tolleson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 92:330-3. 2003
    ..These patients and their outcomes may be more representative of patients with typical acute coronary syndromes undergoing stenting in clinical practice...
  34. doi request reprint Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease
    Mark Y Chan
    Duke Clinical Research Institute, Durham, North Carolina, USA
    JACC Cardiovasc Interv 1:369-78. 2008
    ..We sought to characterize the utilization and impact of a conservative medical management strategy for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) and significant coronary artery disease on early angiography...
  35. ncbi request reprint Postmenopausal hormone use in women with acute coronary syndromes
    Elizabeth Parsons
    Duke University School of Medicine, Durham, North Carolina, USA
    J Womens Health (Larchmt) 13:863-71. 2004
    ..Recent trials reveal no benefit and possible harm from chronic hormone replacement therapy (HRT). Less is known about intermediate-term outcomes associated with HRT use in the setting of acute coronary syndromes (ACS)...
  36. ncbi request reprint Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
    John L Petersen
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 148:269-76. 2004
    ..It is hoped that the SYNERGY Library will serve as a model for future substudy design to maximize academic insight within the framework of a large-scale, multicenter trial...
  37. doi request reprint Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
    Emmanouil S Brilakis
    Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 102:552-8. 2008
    ..In conclusion, compared with patients with ACS without previous CABG, those with previous CABG have a higher risk for adverse cardiac events and may derive similar benefit from intensive statin therapy...
  38. ncbi request reprint Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial
    Michael S Cuffe
    Northwestern University Medical School, Division of Cardiology, 201 E Huron St, Galter 10 240, Chicago, IL 60611, USA
    JAMA 287:1541-7. 2002
    ..Although intravenous inotropic therapy usually produces beneficial hemodynamic effects and is labeled for use in the care of such patients, the effect of such therapy on intermediate-term clinical outcomes is uncertain...
  39. doi request reprint Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:235-44. 2009
    ....
  40. doi request reprint Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database
    John L Petersen
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
    Am Heart J 159:462-470.e1. 2010
    ..Relationships between long-term use and level of dual antiplatelet therapy and outcomes after drug-eluting stent implantation are not well established...
  41. ncbi request reprint Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction
    Manesh R Patel
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 151:316-22. 2006
    ..Cardiac tamponade is a life-threatening complication of acute myocardial infarction (MI). Data on the incidence, risk factors, and outcome of tamponade in patients with acute MI in the fibrinolytic era are limited...
  42. ncbi request reprint Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report
    Karina W Davidson
    Department of Medicine, Columbia University College of Physicians and Surgeons, 622 W 168th St, PH9 Center, Room 941, New York, NY 10032, USA
    Psychosom Med 68:645-50. 2006
    ..The National Heart, Lung, and Blood Institute convened an interdisciplinary working group of experts to develop recommendations for the assessment and treatment of depression in patients with coronary heart disease (CHD)...
  43. ncbi request reprint A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22
    Stephen D Wiviott
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 113:1406-14. 2006
    ..We analyzed the design, implementation, and results of the two trials in an attempt to clarify the effects of early intensive statin therapy...
  44. ncbi request reprint Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial
    Chadwick D Miller
    Department of Emergency Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Eur Heart J 28:1079-84. 2007
    ..We compared the initial treatment and clinical outcomes of patients presenting with evolving MI (EMI) with those presenting with MI...
  45. ncbi request reprint Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Rajesh Janardhanan
    Division of Cardiology, Brigham and Women s Hospital, Boston, MA02115, USA
    Am Heart J 152:183-9. 2006
    ..It is not known, however, whether the extent of coronary artery disease (CAD) independently influences cardiovascular (CV) outcomes in these high-risk patients...
  46. ncbi request reprint Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients
    Padma Kaul
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    J Am Coll Cardiol 41:371-80. 2003
    ....
  47. ncbi request reprint Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery
    Abhinav Goyal
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Thorac Surg 83:993-1001. 2007
    ..We investigated whether greater use of secondary prevention medications after coronary artery bypass graft surgery is associated with improved clinical outcomes...
  48. doi request reprint Determining the most appropriate components for a composite clinical trial outcome
    M Angelyn Bethel
    Division of Endocrinology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Am Heart J 156:633-40. 2008
    ..This may not be true if the intervention has a lesser effect on some components of the composite. Consequently, treatment effect size may depend on the choice of composite...
  49. ncbi request reprint Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank)
    CHRISTOPHER M O'CONNOR
    Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 90:101-7. 2002
    ..Thus, regardless of the severity of coronary disease, heart failure symptoms, or ventricular dysfunction, CABG provides extended event-free and survival advantage over medical therapy alone in patients with an ischemic cardiomyopathy...
  50. ncbi request reprint Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 152:500-8. 2006
    ..By examining this international trial population of high-risk patients, we sought to determine geographic variations in the use of 3 key treatments for MI...
  51. ncbi request reprint Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
    John L Petersen
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 292:89-96. 2004
    ....
  52. ncbi request reprint The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events
    L Kristin Newby
    Duke Clinical Research Institute, Durham, North Carolina 27707, USA
    Am J Med 112:647-58. 2002
    ..To understand these findings, we performed a meta-analysis of results from four phase 3 trials...
  53. ncbi request reprint Part I: Identifying holes in the safety net
    J Conor O'Shea
    Duke Center for Education and Research on Therapeutics CERTs Research Center, Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 147:977-84. 2004
  54. ncbi request reprint Conducting economic evaluations alongside multinational clinical trials: toward a research consensus
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke University Medical Centre, Durham, NC, USA
    Am Heart J 149:434-43. 2005
    ..Delineation of the various approaches to multinational economic evaluation may assist researchers, peer reviewers, journal editors, and decision makers in evaluating the strengths and limitations of particular studies...
  55. ncbi request reprint Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
    Robert M Califf
    Duke Transitional Medicine Institute, Durham, NC 27715, USA
    Am Heart J 156:623-32. 2008
    ..The study was designed to evaluate whether reducing postprandial hyperglycemia, blockade of the renin-angiotensin-aldosterone system, or both interventions reduce the risk of T2DM or cardiovascular events in patients with IGT...
  56. ncbi request reprint Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction
    Richard E Waters
    Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 43:2153-9. 2004
    ..Consequently, this current evolution of reperfusion strategies has the potential to further reduce morbidity and mortality for patients presenting with STEMI...
  57. ncbi request reprint Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)
    Melvin R Echols
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 99:315-21. 2007
    ..African-American patients had significantly better adjusted 30-day outcomes but similar 6-month outcomes compared with white patients...
  58. doi request reprint Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes
    Jason N Katz
    Department of Medicine, Division of Cardiology and Pulmonary and Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Crit Care Med 38:375-81. 2010
    ..To describe long-term temporal trends in patient characteristics, processes of care, and in-hospital outcomes among unselected admissions within the contemporary coronary care unit...
  59. ncbi request reprint Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial
    Cynthia Binanay
    Duke Clinical Research Institute, Durham, NC, USA
    JAMA 294:1625-33. 2005
    ..Pulmonary artery catheters (PACs) have been used to guide therapy in multiple settings, but recent studies have raised concerns that PACs may lead to increased mortality in hospitalized patients...
  60. ncbi request reprint Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials
    John M Galla
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 151:16-24. 2006
    ..A concomitant goal was to contribute insight to the debate over how patients with NSTE ACS should be managed...
  61. ncbi request reprint Predicting significant coronary artery disease in patients with left ventricular dysfunction
    David J Whellan
    Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
    Am Heart J 152:340-7. 2006
    ..The objective of this study was to develop a model to assist clinicians in determining the likelihood of CAD before cardiac catheterization...
  62. ncbi request reprint Depression and ischemic heart disease: what have we learned so far and what must we do in the future?
    Wei Jiang
    Department of Internal Medicine and Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 150:54-78. 2005
  63. doi request reprint Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)
    James M Yau
    Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 102:546-51. 2008
    ..Further research is needed into the prevention and treatment of perioperative MI in patients undergoing CABG...
  64. ncbi request reprint Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction
    Arthur C P Maas
    Duke University Medical Center, Durham, NC, USA
    Am Heart J 147:698-704. 2004
    ....
  65. ncbi request reprint Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries
    R David Anderson
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 144:81-8. 2002
    ..Whether prognostically useful information can be achieved as early as 90 minutes after thrombolysis is unknown...
  66. ncbi request reprint Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial)
    David E Kandzari
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 93:458-61. 2004
    ..4, 95% confidence interval 1.2 to 10.2). Because facial or head trauma may greatly influence treatment decisions, this risk factor should be incorporated into models designed to estimate the risks and benefits of fibrinolytic therapy...
  67. ncbi request reprint Risk stratification after hospitalization for decompensated heart failure
    G Michael Felker
    Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Card Fail 10:460-6. 2004
    ..We used data from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study to develop a model that would predict outcomes in patients with decompensated HF...
  68. ncbi request reprint Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27710, USA
    JAMA 293:1746-50. 2005
    ..Incorrect dosing of alteplase has been associated with worse clinical outcomes in patients. However, patients at high risk of adverse events are more prone to dosing errors, thus confounding this relationship...
  69. ncbi request reprint Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II
    Sana M Al-Khatib
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Ann Intern Med 142:593-600. 2005
    ..3 or less...
  70. doi request reprint Improving the quality of care for women with cardiovascular disease: report of a DCRI Think Tank, March 8 to 9, 2007
    Jeffrey S Berger
    Duke Clinical Research Institute and the Division of Cardiovascular Medicine, Duke University, Durham, NC 27715, USA
    Am Heart J 156:816-25, 825.e1. 2008
    ..Nevertheless, little attention has focused on improving the quality of healthcare in women compared with other areas of cardiovascular medicine...
  71. ncbi request reprint Improving communication of drug risks to prevent patient injury: proceedings of a workshop
    William H Campbell
    University of North Carolina at Chapel Hill CERTs Center, Durham, NC 27715, USA
    Pharmacoepidemiol Drug Saf 12:183-94. 2003
    ..This paper presents the results of the first workshop in the series, a 2-day meeting focused on communication of drug risks to healthcare professionals and patients...
  72. ncbi request reprint Principles from clinical trials relevant to clinical practice: Part II
    Robert M Califf
    Duke Clinical Research Institute and the Division of Cardiology, Duke University Medical Center, Durham, NC, USA
    Circulation 106:1172-5. 2002
  73. ncbi request reprint Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials
    Mauricio G Cohen
    Division of Cardiology, University of North Carolina at Chapel Hill, 130 Mason Farm Road, CB 7075, Bioinformatics Building Suite 4128, Chapel Hill, NC 27599, USA
    Am J Med 118:482-8. 2005
    ..To correlate pulmonary artery catheterization (PAC) use and 30-day outcomes and to characterize the use of pulmonary artery catheters among patients with acute coronary syndromes (ACS)...
  74. doi request reprint Circumstances and outcomes of sudden unexpected death in patients with high-risk myocardial infarction: implications for prevention
    Siqin Ye
    Division of Cardiology, New York Presbyterian Columbia University Medical Center, New York, NY 10032, USA
    Circulation 123:2674-80. 2011
    ..Sudden death (SD) is a frequent catastrophic complication in patients after myocardial infarction. Circumstances of SD may affect strategies for prevention...
  75. doi request reprint Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial
    Ka Sing Lawrence Wong
    From the Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China K S L W Heart Center, Peking University People s Hospital, Beijing, China D Y H Department of Cardiology, Apollo Hospital, Chennai, India A O National Heart Centre, Singapore, Singapore R S T Department of Medicine, Division of Cardiology, Duke Clinical Research Institute M R P, K W M, R C B and Department of Medicine, Division of Cardiology, Duke Translational Medicine Institute R C, Duke University Medical Center, Durham, NC Department of Epidemiology, Massachusetts General Hospital and Harvard Medical School, Boston D E S Department of Cardiovascular Medicine, University Hospital Munster, Munster, Germany G B Centre for Cardiovascular Science, University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, Scotland K A A F Bayer HealthCare Pharmaceuticals, Montville, NJ S D B Department of Neurology, Ruprecht Karls University, Heidelberg, Germany W H and Stroke Unit, Department of Neurology, Royal Perth Hospital, University of Western Australia, Perth, Australia G J H
    Stroke 45:1739-47. 2014
    ....
  76. ncbi request reprint The Child and Adolescent Psychiatry Trials Network (CAPTN)
    John S March
    Department of Psychiatry and Behavioral Sciences and the Duke Clinical Research Institute at Duke University Medical Center, Durham, NC 27710, USA
    J Am Acad Child Adolesc Psychiatry 43:515-8. 2004
    ..The current generation of clinical trials in pediatric psychiatry often fails to maximize clinical utility for practicing clinicians, thereby diluting its impact...
  77. doi request reprint Improving the health of the community: Duke's experience with community engagement
    J Lloyd Michener
    Department of Community and Family Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    Acad Med 83:408-13. 2008
    ....
  78. ncbi request reprint Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 288:2130-5. 2002
    ..Rates of nonfatal ischemic complications were significantly diminished...
  79. doi request reprint Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome
    Steve Leung
    University of Kentucky, Lexington, KY, USA
    Am Heart J 156:177-84. 2008
    ..Smoking remains a major public health issue. We investigated the incidence of smoking and outcomes in high-risk patients with acute coronary syndromes. Differences in treatment effect of antithrombin therapies were also investigated...
  80. ncbi request reprint ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guideli
    Eugene Braunwald
    J Am Coll Cardiol 40:1366-74. 2002
  81. doi request reprint Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both
    L Michael Prisant
    Hypertension and Clinical Pharmacology, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Am Coll Cardiol 51:1865-71. 2008
    ....
  82. doi request reprint High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    Rachel E Anderson
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02445, USA
    Am Heart J 155:706-11. 2008
    ..We examined characteristics, cardiovascular outcomes, and the influence of risk factors on outcomes in young survivors of AMI...
  83. ncbi request reprint Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT
    Wei Ching Chang
    University of Alberta, Edmonton, Alberta, Canada
    Am Heart J 148:62-71. 2004
    ..The objective of the current study was to develop an approach to predicting outcome in NSTE-ACS that could account for the changing nature of risk...
  84. ncbi request reprint ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
    Eugene Braunwald
    Circulation 106:1893-900. 2002
  85. ncbi request reprint Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an
    Wayne B Batchelor
    Tallahassee Heart and Vascular Institute, Tallahassee Memorial Healthcare, Tallahassee, Fla 32308, USA
    Circulation 106:1470-6. 2002
    ..The relative anti-aggregatory effects of currently prescribed platelet glycoprotein IIb/IIIa receptor antagonists during and after percutaneous coronary intervention for acute coronary syndromes have not been established...
  86. ncbi request reprint Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial)
    Marino Labinaz
    University of Ottawa Heart Institute, Ottawa, Ontario, Canada
    Am J Cardiol 90:585-90. 2002
    ..There is no evidence of a statistical interaction in the treatment effect of eptifibatide between patients with and without diabetes...
  87. ncbi request reprint Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 111:3411-9. 2005
    ....
  88. ncbi request reprint Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction
    Ronnier J Aviles
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, OH 44951, USA
    N Engl J Med 346:2047-52. 2002
    ..However, there is concern that renal dysfunction may impair the prognostic value, because cardiac troponin T may be cleared by the kidney...
  89. ncbi request reprint Prognostic significance of elevated troponin I after percutaneous coronary intervention
    Warren J Cantor
    Division of Cardiology, St Michael s Hospital, 30 Bond Street, Toronto, Ontario, Canada M5B 1W8
    J Am Coll Cardiol 39:1738-44. 2002
    ..We sought to assess the incidence and clinical significance of elevated cardiac troponin I (cTnI) after percutaneous coronary intervention (PCI)...
  90. ncbi request reprint Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial
    Marino Labinaz
    University of Ottawa Heart Institute, Ottawa, Ontario, Canada
    Circulation 105:322-7. 2002
    ..90 [95% CI, 0.67 to 1.20]) and in patients without a history of CABG (unadjusted HR, 0.89 [95% CI, 0.80 to 0.99])...
  91. ncbi request reprint Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT)
    M Ashequl Islam
    Geisinger Medical Center, Danville, Pennsylvania 17822, USA
    Am J Cardiol 90:916-21. 2002
    ..5% vs 10.7%; p = 0.007). In summary, abciximab (compared with placebo) significantly reduced angiographic complications during coronary stenting. Abciximab also prevented CK-MB elevations in patients without angiographic complications...
  92. ncbi request reprint Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal
    Warren J Cantor
    Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Catheter Cardiovasc Interv 69:73-83. 2007
    ..Our objective was to analyze the impact of arterial access site, sheath size, timing of sheath removal, and use of access site closure devices on high-risk patients with acute coronary syndromes (ACS)...
  93. doi request reprint Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters
    Stephen A Olenchock
    Cardiothoracic Surgery Department, Tufts University School of Medicine and Caritas St Elizabeth s Medical Center, Boston, Massachusetts, USA
    Ann Thorac Surg 85:520-4. 2008
    ..The goal of the present analysis was to evaluate the association of SVG markers with clinical outcomes and graft patency...
  94. doi request reprint Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV
    Mitchell J Magee
    Cardiopulmonary Research Science and Technology Institute, Dallas, Texas, USA
    Ann Thorac Surg 85:494-9; discussion 499-500. 2008
    ....
  95. ncbi request reprint Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes
    Cheuk Kit Wong
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    J Am Coll Cardiol 46:29-38. 2005
    ....
  96. ncbi request reprint Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarct
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Circulation 112:3391-9. 2005
    ..Those with heart failure or impaired left ventricular left ventricular function after acute myocardial infarction have high complication and mortality rates. Little is known about outcomes with contemporary therapies in these patients...
  97. ncbi request reprint Lessons learned from a clinical trial
    Paul W Armstrong
    University of Alberta, Edmonton, Alberta, Canada
    Circulation 110:3610-4. 2004
  98. ncbi request reprint A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting
    Mina Madan
    Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Can J Cardiol 20:1343-9. 2004
    ..Few data are available comparing PCI outcomes between the two countries in the era of coronary stenting and adjunctive glycoprotein IIb/IIIa inhibition...
  99. ncbi request reprint Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction
    Lars Køber
    Department of Cardiology, Non Invasive Lab, Rigshospitalet, 9 Blegdamsvej, Copenhagen, Denmark
    Eur J Heart Fail 8:591-8. 2006
    ....
  100. ncbi request reprint Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction
    Nagesh S Anavekar
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 351:1285-95. 2004
    ..Renal failure is associated with one of the highest risks, but the influence of milder degrees of renal impairment is less well defined...

Research Grants1

  1. ESCAPE Mechanistic Substudies
    Robert Califf; Fiscal Year: 2003
    ..Catecholamines are also being collected at baseline and 3 months. In addition, the ESCAPE investigators are all ready capturing detailed demographic, clinical, and physiological information as part of the protocol for the primary study. ..